Sources: 44NIH Clinical Center, 4ClinicalTrials, 65UMLS, 43NDF-RT, 13DrugBank, 26HMDB, 9DGIdb, 53PharmGKB, 30IUPHAR, 47Novoseek, 1BitterDBSee all MalaCards sources |
Drugs for Malignant Peripheral Nerve Sheath Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show top 50)
(show all 94)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Cyclophosphamide | approved, investigational | Phase 3, Phase 2 | 2643 | 50-18-0, 6055-19-2 | 2907 | (+-)-Cyclophosphamide (-)-Cyclophosphamide (RS)-Cyclophosphamide 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin 2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide 4-Hydroxy-cyclophosphan-mamophosphatide 50-18-0 60007-95-6 6055-19-2 (monohydrate) 75526-90-8 AC1L1EQQ AI3-26198 ASTA ASTA B518 Asta B 518 B 518 B-518 BRN 0011744 BSPBio_002099 Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester C 0768 C07888 C7H15Cl2N2O2P CB 4564 CB-4564 CCRIS 188 CHEBI:4027 CHEMBL32520 CHEMBL88 CID2907 CP CPA CTX CY Ciclofosfamida Ciclofosfamida [INN-Spanish] Ciclofosfamide Ciclophosphamide Ciclophosphamide [INN] Clafen Claphene Cycloblastin Cyclophosphamid Cyclophosphamide Cyclophosphamide (INN) Cyclophosphamide (TN) Cyclophosphamide (anhydrous form) Cyclophosphamide (anhydrous) Cyclophosphamide Monohydrate Cyclophosphamide Sterile Cyclophosphamide anhydrous Cyclophosphamide, (+-)-Isomer Cyclophosphamides Cyclophosphamidum Cyclophosphamidum [INN-Latin] Cyclophosphan Cyclophosphane Cyclophosphanum Cyclophosphoramide Cyclostin Cyklofosfamid Cyklofosfamid [Czech] Cytophosphan Cytophosphane Cytoxan Cytoxan (TN) Cytoxan Lyoph D,L-Cyclophosphamide D07760 DB00531 | DivK1c_000246 EINECS 200-015-4 EU-0100238 Endoxan Endoxan R Endoxan-Asta Endoxana Endoxanal Endoxane Enduxan Genoxal HMS2090A12 HSDB 3047 Hexadrin IDI1_000246 KBio1_000246 KBio2_001338 KBio2_003906 KBio2_006474 KBio3_001319 KBioGR_000888 KBioSS_001338 LS-1302 LS-99787 Ledoxina Lopac-C-0768 Lopac0_000238 Lyophilized Cytoxan Mitoxan MolPort-001-783-420 N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide NCGC00015209-01 NCGC00015209-03 NCGC00015209-06 NCGC00091741-02 NCGC00091741-03 NCI-C04900 NCI60_002097 NINDS_000246 NSC 26271 NSC-26271 NSC26271 NSC273033 NSC273034 Neosar Occupation, cyclophosphamide exposure Procytox RCRA waste no. U058 Rcra Waste Number U058 Rcra waste number U058 Revimmune S1217_Selleck SK 20501 SPBio_001071 STK177249 STOCK2S-91217 Semdoxan Sendoxan Senduxan Spectrum2_001146 Spectrum3_000370 Spectrum4_000304 Spectrum5_000795 Spectrum_000858 UNII-6UXW23996M WLN: T6MPOTJ BO BN2G2G Zyklophosphamid Zyklophosphamid [German] bis(2-Chloroethyl)phosphami de cyclic propanolamide bis(2-Chloroethyl)phosphamide cyclic propanolamide ester cyclophosphamide | |
| | 2 | | Carboplatin | approved | Phase 3 | 1885 | 41575-94-4 | 10339178, 498142, 38904 | (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum /h1-3H2,(H,7,8)(H,9,10) /q 1,1-Cyclobutanedicarboxylate diammine platinum (II) 1,1-Cyclobutanedicarboxylate diammine platinum(II) 2*-1 2*1H2 41575-94-4 70903-55-8 AC-1457 AC1L8I6U Ambap41575-94-4 BSPBio_003145 C 2538 C2043 C2538_SIGMA C6H10N2O4Pt CBDCA CCRIS 3404 CHEBI:31355 CHEMBL1351 CHEMBL288376 CID10339178 CID2567 CID38904 CID426756 CID498142 CID5352133 CID6398587 CID6603770 Carbopaltin Carboplatin Carboplatin (JAN/USP/INN) Carboplatin (USAN) Carboplatin [USAN:INN:BAN:JAN] Carboplatine Carboplatine [French] Carboplatino Carboplatino [Spanish] Carboplatinum Carboplatinum [Latin] Cbdca Cyclobutane-1,1-dicarboxylate D01363 DB00958 Diammine(1,1-cyclobutanedicarboxylato)platinum (II) Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum Diammine-1,1-cyclobutane dicarboxylate platinum II DivK1c_000892 EINECS 255-446-0 EU-0100230 Ercar HMS1921J16 HMS2090M05 HMS2092B22 HMS502M14 HSDB 6957 I14-2390 IDI1_000892 IUPAC: Azane InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6 | JM 8 JM-8 KBio1_000892 KBio2_002009 KBio2_004577 KBio2_007145 KBio3_002645 KBioGR_000713 KBioSS_002009 LS-117689 Lopac-C-2538 Lopac0_000230 MolPort-003-665-501 MolPort-003-845-609 NCGC00015223-01 NCGC00093695-01 NCGC00094961-01 NCGC00094961-02 NCGC00094961-03 NCGC00162099-01 NCGC00162099-02 NCGC00167800-01 NCGC00178242-01 NINDS_000892 NSC 201345 NSC 241240 NSC-241240 NSC201345 NSC241240 Paraplatin Paraplatin (TN) Paraplatin, Carboplatin Paraplatin-AQ Platinum(+2) Cation Platinum(II), (1, 1-cyclobutanedicar Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2) Platinum, {diammine[1,1-cyclobut S1215_Selleck SPBio_000716 SPECTRUM1502106 Spectrum2_000898 Spectrum3_001503 Spectrum4_000337 Spectrum5_001094 Spectrum_001529 UNII-BG3F62OND5 azanide carboplatin cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II) cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii) cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II) cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II) cis-Diammine(1,1-cyclobutanedicarboxylato) platinum cis-Diammine(1,1-cyclobutanedicarboxylato)platinum cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) cis-Diammine(cyclobutanedicarboxylato)platinum II cyclobutane-1,1-dicarboxylic acid diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum nchembio.573-comp10 nchembio773-comp2 nchembio873-comp3 platinum(2+) |
| | 3 | | Etoposide | approved | Phase 3, Phase 2 | 1169 | 33419-42-0 | 36462 | (-)-Etoposide 121471-01-0 136598-18-0 201594-04-9 33419-42-0 35317-32-9 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside) 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) 4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside 4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside 51854-34-3 76576-58-4 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one AB00438905 AC1L1FN8 AC1L1VT3 AC1L6246 AC1NR4OG AC1O4WGG AC1O7M1N AC1Q47JJ Ambap33419-42-0 BPBio1_000673 BRD-K37798499-001-02-5 BSPBio_000611 Bio1_000489 Bio1_000978 Bio1_001467 C01576 CCRIS 2392 CHEBI:4911 CHEBI:588795 CHEMBL44657 CID11758093 CID284997 CID3310 CID36462 CID5284558 CID6419930 CID6610299 CPD000112002 D00125 DB00773 DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE, Demethyl Epipodophyllotoxin Ethylidine Glucoside Demethyl-epiodophyllotoxin ethylidene glucoside Demethylepipodophyllotoxin-beta-D-ethylideneglucoside E0675 E1383_SIGMA EINECS 251-509-1 EPE EPEG ETOP Epipodophyllotoxin Epipodophyllotoxin VP-16213 Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI) Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside) Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside) Eposide Eposin Eposin, Vepesid, VP-16, Toposar, Etoposide | Etopol Etopophos Etopophos (phosphate salt) Etoposid Etoposide Etoposide (JP15/USP/INN) Etoposide (VP16) Etoposide Phosphate Etoposide [USAN:INN:BAN:JAN] Etoposido Etoposido [INN-Spanish] Etoposidum Etoposidum [INN-Latin] Etosid HMS1569O13 HMS2052N05 HMS2089F14 HSDB 6517 I06-0248 KBioSS_002410 LS-1214 Lastet MLS000049957 MLS001074951 MLS001424283 MLS002153463 MLS002207239 MLS002222184 MolPort-003-983-431 MolPort-004-905-001 MolPort-004-955-161 NCGC00025056-02 NChemBio.2007.10-comp19 NK 171 NSC 141540 NSC-141540 NSC141540 Prestwick0_000396 Prestwick1_000396 Prestwick2_000396 Prestwick3_000396 Prestwick_211 S1225_Selleck SAM001246880 SMR000112002 SPBio_002532 ST056353 Toposar UNII-6PLQ3CP4P3 VP 16 VP 16 (pharmaceutical) VP 16-213 VP 16213 VP-16 VP-16-213 VePESID (TN) VePesid Vepesid Vepesid J Vepeside ZINC03830818 ZINC03938684 Zuyeyidal etoposide nchembio.573-comp8 nchembio873-comp2 trans-Etoposide | |
| | 4 | | Dactinomycin | approved | Phase 3 | 46 | 50-76-0 | 2019, 457193 | (- )-actinomycin d (-)-actinomycin d -pentone 01815_FLUKA 1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine 2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-I)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide 4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide 50-76-0 A1410_SIGMA A4262_SIGMA A9415_SIGMA AC1L1CQX AC1L9W52 ACT ACT D ACTINOMYCIN D ACTINOMYCIN D AMP ACTINOMYCIN-D ACTO-D ACon0_000471 ACon1_001004 AD AD (VAN) AI3-26374 ActD Actactinomycin A IV Actactinomycin a Iv Actinomycin 11 Cosmegen Actinomycin 11 cosmegen Actinomycin 7 Actinomycin A IV Actinomycin Aiv Actinomycin C (sub1) Actinomycin C(sub1) Actinomycin C1 Actinomycin D Actinomycin D (JP15) Actinomycin D deriv. of 3H-phenoxaocardazine Actinomycin D, sodium deoxyribonucleic acid complex Actinomycin I Actinomycin I (sub1) Actinomycin I(sub 1) Actinomycin I(sub1) Actinomycin I1 Actinomycin IV Actinomycin Iv Actinomycin X 1 Actinomycin X1 Actinomycin iv Actinomycin-(threo-val-pro-sar-meval) Actinomycin-?IV Actinomycin-[threo-val-pro-sar-meval] Actinomycindioic D Acid, Dilactone Actinomycindioic D acid, dilactone Acto-D Antibiotic From Streptomyces Parvullus Antibiotic from Streptomyces parvullus BCBcMAP01_000155 BRD-A42383464-001-02-2 Bio1_000342 Bio1_000831 Bio1_001320 C06770 C1 C62H86N12O16 CBiol_002056 CCRIS 9 CHEBI:123721 CHEBI:27666 CHEMBL1554 CHEMBL427947 CID2019 | CID457193 COSMEGEN (TN) CPD000469227 Chounghwamycin B Cosmegen D Actinomycin D00214 DACTINOMYCIN DB00970 DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA Dactinomicina Dactinomicina [INN-Spanish] Dactinomycin Dactinomycin (USP) Dactinomycin D Dactinomycin [USAN:BAN] Dactinomycine Dactinomycine [INN-French] Dactinomycinum Dactinomycinum [INN-Latin] Dilactone Actinomycin D Acid Dilactone Actinomycindioic D Acid Dilactone actin omycindioic D acid Dilactone actinomycin D acid Dilactone actinomycindioic D acid EINECS 200-063-6 FT-0080366 GNF-PF-1977 HBF 386 HBF 386 Meractinomycin HBF 386 meractinomycin HMS2052O17 HSDB 3220 LMPK14000005 LS-142 Lyovac Cosmegen Lyovac cosmegen MEGxm0_000350 MLS001424196 Meractinomycin MolPort-001-739-741 MolPort-003-925-177 NCGC00025059-02 NCGC00090796-01 NCGC00161622-01 NCGC00161622-02 NCGC00169767-01 NCI-C04682 NCI60_030539 NP-005932 NSC 3053 NSC-3053 NSC191297 NSC3053 Neuro_000003 Oncostatin K Oxamide PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA SAM001246846 SMP1_000005 SMR000469227 UNII-1CC1JFE158 UPCMLD-DP055 UPCMLD-DP055:001 UPCMLD-DP055:002 WLN: 16- AN FVN IVN LVO PVM SVTJ G1 J1 KY1&1 N1 RY1&1 X 97 actd actinomycin D actinomycin cl actinomycin x i actinomyein-theo-val-pro-sar-meval dactinomyein d o)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine |
| | 5 | | Vincristine | approved, investigational | Phase 3 | 863 | 2068-78-2, 57-22-7 | 5978 | 22-Oxovincaleukoblastin 22-Oxovincaleukoblastine 28379-27-3 57-22-7 AC1L1LJC C07204 C46H56N4O10 CCRIS 5763 CHEBI:28445 CID5978 D08679 DB00541 EINECS 200-318-1 HMS2090E19 HSDB 3199 Indole alkaloid LCR LS-228 Leurocristine Lilly 37231 (1:1 sulfate salt) Liposomal Vincristine Marqibo NCGC00163700-01 NCI-C04864 NCI60_026703 NSC-67574 Onco TCS | Oncovin Oncovin (1:1 sulfate salt) Oncovine Tecnocris Tecnocris (TN) UNII-5J49Q6B70F VCR VIN Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine Vincasar Vincasar (1:1 sulfate salt) Vincasar PFS Vincrex Vincrex (1:1 sulfate salt) Vincristin Vincristina Vincristina [DCIT] Vincristine (INN) Vincristine Sulfate Vincristine Sulfate PFS Vincristine [INN:BAN] Vincristinum Vincristinum [INN-Latin] Vincrstine Vincrystine Vinkristin Z-D-Val-Lys(Z)-OH vincristine | |
| | 6 | | Trabectedin | approved, investigational | Phase 3, Phase 2 | 58 | 114899-77-3 | 108150 | | Ecteinascidin 743 NSC 684766 SID144206315 SID144206787 Yondelis |
| | 7 | | Dacarbazine | approved, investigational | Phase 3, Phase 2 | 411 | 4342-03-4 | 5351166 | (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide (Dimethyltriazeno)imidazolecarboxamide 37626-23-6 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide 4-(Dimethyltriazeno)imidazole-5-c arboxamide 4-(Dimethyltriazeno)imidazole-5-carboxamide 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide 4342-03-4 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide 5-(Dimethyltriazeno)-4-imidazolecarboxamide 5-(Dimethyltriazeno)imidazole-4-carboxamide 5-(Dimethyltriazeno)imidazole-4-carboximide 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide 94361-71-4 AC1NQXVV AC1NS01W AC1NS4BN AI3-52825 BPBio1_000428 BRD-K35520305-001-07-8 BSPBio_000388 BSPBio_002091 Biocarbazin Biocarbazine Biocarbazine R C6H10N6O CAS-891986 CCRIS 190 CHEBI:4305 CHEMBL476 CID5281007 CID5351166 CID5353562 Carboxamide, Dimethyl Imidazole D00288 D003606 D2390_SIGMA D3634 DB00851 DIC DTCI DTIC DTIC Dome DTIC, DTIC-Dome, Dacarbazine DTIC-Dome DTICDome DTIE Dacarbazin Dacarbazina Dacarbazine Dacarbazine (JAN/USP/INN) Dacarbazine [USAN:INN:BAN:JAN] Dacarbazino Dacarbazino [INN-Spanish] Dacarbazinum Dacarbazinum [INN-Latin] | Dacatic Decarbazine Deticene Di-me-triazenoimidazolecarboxamide Di-methyl-triazenoimidazolecarboxamide Dimethyl Imidazole Carboxamide Dimethyl Triazeno Imidazole Carboxamide Dimethyltriazenoimidazolecarboxamide DivK1c_000326 Dtic-Dome Dtic-Dome (TN) Dtic-dome (tn) EINECS 224-396-1 HE1150000 HMS1569D10 HMS2090A20 HMS2091I20 HMS501A08 HSDB 3219 I06-2280 I14-1659 ICDMT ICDT IDI1_000326 Imidazole Carboxamide Imidazole Carboxamide, Dimethyl Imidazole carboxamide KBio1_000326 KBio2_001364 KBio2_003932 KBio2_006500 KBio3_001311 KBioGR_000896 KBioSS_001364 LS-119 MLS001332543 MLS001332544 MolPort-003-666-153 MolPort-003-846-120 MolPort-006-709-420 NCGC00016986-01 NCGC00091861-01 NCGC00091861-02 NCGC00091861-03 NCGC00091861-04 NCI-C04717 NCI60_004053 NCIMech_000261 NINDS_000326 NIOSH/HE1150000 NPFAPI-05 NSC 45388 NSC-45388 NSC45388 Prestwick0_000574 Prestwick1_000574 Prestwick2_000574 Prestwick3_000574 Prestwick_904 S1221_Selleck SMP2_000251 SMR000857131 SPBio_001075 SPBio_002607 SPECTRUM1500218 ST51014976 Spectrum2_001148 Spectrum3_000366 Spectrum4_000308 Spectrum5_000823 Spectrum_000884 UNII-7GR28W0FJI WLN: T5M CNJ DVZ ENUNN1&1 dacarbazine | |
| | 8 | | Mechlorethamine | approved | Phase 3, Phase 2, Phase 1 | 309 | 51-75-2 | 4033 | .Beta.,.beta.'-Dichlorodiethyl-N-methylamine 1, 5-Dichloro-3-methyl-3-azapentane hydrochloride 126-85-2 (N-oxide) 2,2'-Dichloro-N-me 2,2'-Dichloro-N-methyldiethylamine 2,2'-Dichlorodiethyl-methylamine 2,2'-dichloro-N-methyldiethylamine 2-Chloro-N-(2-chloroethyl)-N-methylethanamine 302-70-5 (N-oxide, hydrochloride) 51-75-2 55-86-7 (HYDROCHLORIDE) AC1L1H9H Antimit BRN 0605323 BSPBio_001947 Bis(2-chloroethyl)methylamine Bis(beta-chloroethyl) methylamine Bis(beta-chloroethyl)methylamine C07115 C5H11Cl2N CCRIS 447 CHEBI:28925 CHEMBL427 CID4033 Carolysine Caryolysin Caryolysine Chloramine (the nitrogen mustard) Chlorethazine Chlormethine Chlormethine (INN) Chlormethine [INN:BAN] Chlormethinum [INN-Latin] Cloramin Clormetina Clormetina [INN-Spanish] D07671 DB00888 Di(2-chloroethyl)methylamine Dichlor amine Dichloren DivK1c_000759 EINECS 200-120-5 ENT-25294 Embechine Embichin HMS1920J15 HMS2091B04 HMS502F21 HN-2 HN2 HSDB 5083 I14-8708 IBS-L0033631 IDI1_000759 KBio1_000759 KBio2_001369 KBio2_003937 KBio2_006505 KBio3_001447 KBioGR_001448 | KBioSS_001369 LS-7559 MBA Me chloroethamine Mebichloramine Mechlorethamine Mechlorethamine hydrochloride Mechlorethanamine Mechloroethamine Mecloretamina Mecloretamina [Italian] Methylbis(2-chloroethyl)amine Methylbis(beta-chloroethyl)amine Methyldi(2-chloroethyl)amine Mitoxine (*Hydrochloride*) MolPort-001-785-592 Mustargen Mustine Mustine note Mutagen N,N-Bis(2-chloroethyl)-N-methylamine N,N-Bis(2-chloroethyl)methylamine N,N-Di(chloroethyl)methylamine N-Lost N-Methyl lost N-Methyl-2,2'-dichlorodiethylamine N-Methyl-bis(2-chloroethyl)amine N-Methyl-bis(beta-chloroethyl)amine N-Methyl-bis-chloraethylamin N-Methyl-bis-chloraethylamin [German] N-Methyl-lost N-Methyl-lost [German] N-methyl-bis(2-chloroethyl)amine NCGC00091835-02 NCGC00091835-03 NCGC00091835-04 NCGC00091835-05 NCI60_041682 NINDS_000759 NSC762 Nitol (*Hydrochloride*) Nitrogen mustard Nitrogen mustard (HN-2) Nitrogranulogen SPBio_000496 SPECTRUM1500375 Spectrum2_000448 Spectrum3_000484 Spectrum4_000924 Spectrum5_001702 Spectrum_000889 Stickstofflost (*Hydrochloride*) Stickstofflost (ebewe) T 1024 T-1024 TL 146 UNII-50D9XSG0VR Valchlor beta,Beta'-dichlorodiethyl-N-methylamine beta,beta'-Dichlorodiethyl-N-methylamine mechlorethamine thyldiethylamine β,β'-dichlorodiethyl-N-methylamine |
| | 9 | | Epirubicin | approved | Phase 3 | 361 | 56420-45-2 | 41867 | (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside (7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione 4'-Epi-DXR 4'-Epiadriamycin 4'-Epidoxorubicin 4'-epi-DX 4'-epi-Doxorubicin 4'-epidoxorubicin 4-Epidoxorubicin 56390-09-1 56390-09-1 (hydrochloride) 56420-45-2 57918-25-9 AC1L26NP AC1Q6JIV BRN 1445813 C11230 C27H29NO11 CCRIS 2261 CHEBI:47898 CHEMBL417 CID41867 D07901 DB00445 Ellence Epi-DX Epi-Dx Epiadriamycin Epidoxorubicin Epirubicin | Epirubicin (INN) Epirubicin [INN:BAN] Epirubicina Epirubicina [INN-Spanish] Epirubicina [Spanish] Epirubicine Epirubicine [French] Epirubicine [INN-French] Epirubicinum Epirubicinum [INN-Latin] Epirubicinum [Latin] Farmorubicin (TN) HSDB 6962 IMI 28 LS-187190 LS-93992 MLS000759412 NChemBio.2007.10-comp15 NSC 256942 NSC-256942 NSC256942 Pharmorubicin Pfs Pidorubicin Pidorubicina Pidorubicina [INN-Spanish] Pidorubicine Pidorubicine [INN-French] Pidorubicinum Pidorubicinum [INN-Latin] Ridorubicin SMR000466308 Triferric doxorubicin UNII-3Z8479ZZ5X WP 697 | |
| | 10 | | Doxorubicin | approved, investigational | Phase 3, Phase 2, Phase 1 | 1582 | 23214-92-8 | 31703 | (1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside (8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione 111266-55-8 14-Hydroxydaunomycin 14-Hydroxydaunorubicine 14-hydroxydaunomycin 14-hydroxydaunorubicine 23214-92-8 23257-17-2 24385-08-8 25311-50-6 25316-40-9 25316-40-9 (hydrochloride) 29042-30-6 AC1L1M5T AC1Q29OJ ADM ADR Adriablastin Adriacin (hydrochloride salt) Adriamycin Adriamycin PFS Adriamycin PFS (hydrochloride salt) Adriamycin RDF Adriamycin RDF (hydrochloride salt) Adriamycin Semiquinone Adriamycin semiquinone Adriblas tina Adriblastin Adriblastina Adriblastina (TN) Adriblastina (hydrochloride salt) Aerosolized Doxorubicin BPBio1_000502 BRD-K92093830-003-04-3 BSPBio_000456 BSPBio_001031 C01661 C27H29NO11 CCRIS 739 CHEBI:28748 CHEMBL179 CID31703 Caelyx Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74 Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120 D03899 DB00997 DM2 DOX-SL Doxil Doxo Doxorubicin Doxorubicin (USAN/INN) Doxorubicin HCl | Doxorubicin Hydrochloride Doxorubicin [USAN:INN:BAN] Doxorubicin citrate Doxorubicin hydrochloride (hydrochloride salt) Doxorubicin-P4/D10 Doxorubicin-P4/D10 conjugate Doxorubicin-hLL1 Doxorubicin-hLL1 conjugate Doxorubicina Doxorubicina [INN-Spanish] Doxorubicine Doxorubicine [INN-French] Doxorubicinum Doxorubicinum [INN-Latin] EINECS 245-495-6 FI 106 Farmablastina (hydrochloride salt) HMS2089H06 HSDB 3070 Hydroxydaunomycin hydrochlor ide (hydrochloride salt) Hydroxydaunomycin hydrochloride (hydrochloride salt) Hydroxydaunorubicin Hydroxydaunorubicin hydrochloride (hydrochloride salt) JT9100000 LMPK13050001 LS-1029 LS-165655 MLS000759533 Myocet NCI-C01514 NChemBio.2007.10-comp13 NDC 38242-874 NIOSH/JT9100000 NSC 123127 Prestwick0_000438 Prestwick1_000438 Prestwick2_000438 Prestwick3_000438 Probes1_000151 Probes2_000129 RDF Rubex Resmycin Rubex Rubex (hydrochloride salt) SMP1_000106 SPBio_002395 TLC D-99 ThermoDox Triferric doxorubicin UNII-80168379AG adiblastine (hydrochloride salt) adr iablatina (hydrochloride salt) adriablastine (hydrochloride salt) adriablatina (hydrochloride salt) adriblatina (hydrochloride salt) doxorubicin nchembio809-comp5 |
| | 11 | | Ifosfamide | approved | Phase 3, Phase 2, Phase 1 | 371 | 3778-73-2 | 3690 | (+-)-Ifosfamid (+-)-Ifosphamide (+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide (D,L)-Ifosfamide (R,S)-Ifosphamide (R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide 1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide 2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd 2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI) 2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide 3,} 2-oxazaphosphorine oxide 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide 3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide 3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide 36341-88-5 3778-73-2 84711-20-6 A 4942 AB00513932 AC-2113 AC1L1GHW ASTA Z 4942 Ambap3778-73-2 Asta Z 4942 BPBio1_000865 BRN 0611835 BSPBio_000785 C07047 CAS-3778-73-2 CCRIS 352 CHEBI:5864 CHEMBL1024 CID3690 Cyfos D00343 D007069 DB01181 EINECS 223-237-3 HMS1570H07 HMS2090M12 HMS2093N07 HSDB 7023 Holoxan Holoxan 1000 I-Phosphamide I06-0494 IFEX (TN) Ifex Ifosfamid Ifosfamida Ifosfamida [INN-Spanish] Ifosfamide | Ifosfamide (JAN/USP/INN) Ifosfamide Sterile Ifosfamide [USAN:INN:BAN:JAN] Ifosfamidum Ifosfamidum [INN-Latin] Ifosphamide Ifsofamide Iphosphamid Iphosphamid(e) Iphosphamide Iso Endoxan Iso-Endoxan Isoendoxan Isofosfamide Isophosphamide Isosfamide LS-102 LS-99799 MJF 9325 MJF-9325 MLS002154021 Mitoxana Mitoxana, Ifex, Ifosfamide MolPort-003-666-704 N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German] N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine NCGC00016639-01 NCGC00179435-01 NCI-C01638 NCI60_000233 NPFAPI-04 NSC 109,724 NSC 109724 NSC-109,724 NSC-109724 NSC109,724 NSC109724 Naxamide Prestwick0_000833 Prestwick1_000833 Prestwick2_000833 Prestwick3_000833 S1302_Selleck SMR001233348 SPBio_002706 STL058690 UNII-UM20QQM95Y WLN: T6NPOTJ AM2G BO B2G Z 4942 Z-4942 Z4942 ifosfamide isosfamide {3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1, |
| | 12 | | Gemcitabine | approved | Phase 3, Phase 2, Phase 1 | 1881 | 95058-81-4 | 60750 | 103882-84-4 122111-03-9 2',2'-DiF-dC 2',2'-Difluoro-2'-deoxycytidine 2',2'-Difluorodeoxycytidine 2'-Deoxy-.beta.-D-2',2'-difluorocytidine 2'-Deoxy-2',2'-difluorocytidine 4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one 4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one 4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one 95058-81-4 AB1004842 AC1L1TUQ C07650 CCRIS 8984 CHEBI:175901 CHEMBL888 CID60750 Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine D02368 DB00441 DDFC DFDC DFdC DFdCyd Folfugem GEO Gamcitabine GemLip Gemcel | Gemcin Gemcitabin Gemcitabina Gemcitabina [INN-Spanish] Gemcitabine Gemcitabine (USAN/INN) Gemcitabine HCl Gemcitabine Hydrochloride Gemcitabine hydrochloride Gemcitabine stereoisomer Gemcitabinum Gemcitabinum [INN-Latin] Gemtro Gemzar Gemzar (hydrochloride) HMS2089P10 HSDB 7567 Inno-D07001 LS-59139 LY 188011 LY-188011 LY188011 NCGC00168784-01 NChemBio.2007.10-comp25 NSC 613327 NSC613327 TL8005979 UNII-B76N6SBZ8R ZINC18279854 Zefei gemcitabine nchembio.573-comp7 nchembio.90-comp2 |
| | 13 | | Histamine Phosphate | approved | Phase 3 | 906 | 51-74-1 | 65513 | 1H-Imidazole-4-ethanamine, phosphate (1:2) 2-Imidazol-4-ylethylamine orthophosphoric acid (1:2) 4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate) 4-(2-Aminoethyl)imidazole di-acid phosphate 4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate 51-74-1 53623-99-7 74-56-6 AC1L23E4 CID65513 D04445 DB00667 EINECS 200-118-4 | H0147 Histamine Positive Skin Test Control Histamine Positive skin test control Histamine acid phosphate Histamine biphosphate Histamine dihydrogen phosphate Histamine diphosphate Histamine phosphate (1:2) Histamine phosphate (TN) Histamine phosphate (USP) Histamine phosphate [USP] Histamine positive Histaminum LS-78569 UNII-QWB37T4WZZ |
| | 14 | | Cyproheptadine | approved | Phase 3 | 15 | 129-03-3 | 2913 | 1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine 1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine 129-03-3 4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine 4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine 4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine 4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine 41354-29-4 5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene 5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene 5-20-08-00500 (Beilstein Handbook Reference) AC1L1ER8 AKOS004119847 Axoprol BIDD:GT0324 BPBio1_000096 BPBio1_000155 BRD-K28143534-001-01-4 BRD-K28143534-003-03-6 BRN 1685976 BSPBio_000086 Biomol-NT_000131 C06935 CAS-969-33-5 CCRIS 5232 CHEBI:4046 CHEMBL516 CID2913 CYPROHEPTADINE Ciproheptadina Ciproheptadina [INN-Spanish] Ciprovit Ciprovit (TN) Cypoheptadine Cyproheptadiene Cyproheptadin Cyproheptadine Cyproheptadine (INN) | Cyproheptadine Hcl Cyproheptadine Hydrochloride Cyproheptadine [INN:BAN] Cyproheptadinum Cyproheptadinum [INN-Latin] D07765 DB00434 Dibenzosuberonone/Cyproheptadine Dihexazin Dronactin EINECS 204-928-9 Eiproheptadine Glutodina HMS2090P20 HSDB 3048 L001016 LS-114933 Lopac-C-6022 Lopac0_000246 MK 141 MolPort-002-507-777 NCGC00015252-01 NCGC00015252-02 NCGC00015252-03 NCGC00015252-09 NCGC00024293-02 NCGC00024293-04 NCGC00024293-05 Oprea1_498140 PDSP1_001229 PDSP2_001213 Periactin Periactine Periactinol Prestwick0_000103 Prestwick1_000103 Prestwick2_000103 Prestwick3_000103 SPBio_002025 STK802098 Tocris-0996 UNII-2YHB6175DO Viternum nchembio.559-comp10 | |
| | 15 | | Doxil | Approved June 1999 | Phase 3, Phase 2, Phase 1 | 1582 | | 31703 | | Evacet LipoDox Pegylated Liposomal Doxorubicin Hydrochloride liposomal doxorubicin |
| | 16 | | Docetaxel | approved, investigational, Approved May 1996 | Phase 3, Phase 1, Phase 2 | 1844 | 114977-28-5 | 148124, 9877265 | (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate 01885_FLUKA 114977-28-5 4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate AC-383 AC1L3WHJ ANX-514 BIND-014 C11231 CHEBI:4672 CHEMBL92 CID148124 D07866 DB01248 Docefrez Docetaxel Docetaxel (INN) Docetaxel anhydrous Docetaxel, Trihydrate EmDOC | HMS2089K08 InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5 MolPort-003-847-005 N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol N-debenzoyl-N-Boc-10-deacetyl taxol NSC-628503 PSMA-targeted docetaxel nanoparticle RP-56976 SDP-014 TXL Taxotere Taxotere (TN) Taxotere(R) XRP-6976L docetaxel docetaxel 114977-28-5 nchembio.188-comp8 nchembio.2007.34-comp7 nchembio.573-comp11 nchembio853-comp8 | |
| | 17 | | Antibiotics, Antitubercular | | Phase 3, Phase 2, Phase 1 | 5971 | | | | 18 | | Antiviral Agents | | Phase 3, Phase 2, Phase 1 | 8071 | | | | 19 | | Protein Kinase Inhibitors | | Phase 2, Phase 3, Phase 1 | 3162 | | | | 20 | | Anti-Bacterial Agents | | Phase 3, Phase 2, Phase 1 | 9140 | | | | 21 | | Immunosuppressive Agents | | Phase 3, Phase 1, Phase 2 | 10422 | | | | 22 | | Immunologic Factors | | Phase 3, Phase 1, Phase 2 | 18483 | | | | 23 | | Topoisomerase Inhibitors | | Phase 3, Phase 2, Phase 1 | 4081 | | | | 24 | | Imatinib Mesylate | | Phase 2, Phase 3, Phase 1 | 577 | | 123596 | | 25 | | Tubulin Modulators | | Phase 3, Phase 2, Phase 1 | 4279 | | | | 26 | | Etoposide phosphate | | Phase 3, Phase 2 | 1169 | | | | 27 | | Isophosphamide mustard | | Phase 3, Phase 2, Phase 1 | 371 | | | | 28 | | Antineoplastic Agents, Phytogenic | | Phase 3, Phase 2 | 4294 | | | | 29 | | lenograstim | | Phase 3, Phase 2 | 1134 | | | | 30 | | Anti-Infective Agents | | Phase 3, Phase 1, Phase 2 | 17220 | | | | 31 | | Alkylating Agents | | Phase 3, Phase 2, Phase 1 | 3582 | | | | 32 | | Nucleic Acid Synthesis Inhibitors | | Phase 3 | 3836 | | | | 33 | | Antimitotic Agents | | Phase 3, Phase 2, Phase 1 | 4296 | | | | 34 | | Antineoplastic Agents, Alkylating | | Phase 3, Phase 2, Phase 1 | 3406 | | | | 35 | | Antimetabolites, Antineoplastic | | Phase 3, Phase 2, Phase 1 | 5770 | | | | 36 | | Antimetabolites | | Phase 3, Phase 2, Phase 1 | 9454 | | | | 37 | | Histamine H1 Antagonists | | Phase 3 | 688 | | | | 38 | | Neurotransmitter Agents | | Phase 3 | 14795 | | | | 39 | | Serotonin | | Phase 3 | 3147 | 50-67-9 | 5202 | 3-(2-Aminoethyl)-1H-indol-5-ol 3-(2-Aminoethyl)indol-5-ol 3-(b-Aminoethyl)-5-hydroxyindole 5-HT 5-HTA 5-Hydroxy-3-(b-aminoethyl)indole | 5-Hydroxy-tryptamine 5-Hydroxyltryptamine 5-Hydroxytriptamine 5-Hydroxytryptamine Antemovis DS substance Enteramin Enteramine |
| | 40 | | Serotonin Agents | | Phase 3 | 2668 | | | | 41 | | Serotonin Antagonists | | Phase 3 | 1175 | | | | 42 | | Anti-Allergic Agents | | Phase 3 | 1312 | | | | 43 | | Histamine Antagonists | | Phase 3 | 826 | | | | 44 | | Dermatologic Agents | | Phase 3 | 4555 | | | | 45 | | Antipruritics | | Phase 3 | 619 | | | | 46 | | Gastrointestinal Agents | | Phase 3 | 6401 | | | | 47 | | histamine | | Phase 3 | 906 | 75614-87-8, 51-45-6 | 774 | .beta.-Imidazolyl-4-ethylamine 1H-Imidazole-4-ethanamine 1H-Imidazole-5-ethanamine 1avn 1qft 2-(1H-Imidazol-4-yl)ethanamine 2-(1H-Imidazol-4-yl)ethylamine 2-(1H-Imidazol-5-yl)ethanamine 2-(1H-Imidazol-5-yl)ethylamine 2-(1H-imidazol-4-yl)ethan-1-amine 2-(1H-imidazol-5-yl)ethanamine 2-(3H-Imidazol-4-yl)-ethylamine 2-(4-Imidazolyl)ethanamine 2-(4-Imidazolyl)ethylamine 2-Imidazol-4-yl-Ethylamine 2-Imidazol-4-ylethylamine 2-[4-Imidazolyl]ethylamine 4-(2-Aminoethyl)-1H-imidazole 4-(2-Aminoethyl)imidazole 4-Imidazoleethylamine 5-Imidazoleethylamine 51-45-6 53290_FLUKA 64422-25-9 924364-91-0 AC-13185 AC1L19ZT AC1Q54BV AC1Q54BW AKOS000274386 ALBB-005968 BCBcMAP01_000250 BSPBio_001117 BSPBio_002124 Bio1_000487 Bio1_000976 Bio1_001465 Bio2_000389 Bio2_000869 C00388 CCRIS 6535 CHEBI:18295 CHEMBL90 CID774 D08040 DivK1c_000308 EINECS 200-100-6 Eramin Ergamine Ergotidine F411C768-A159-4FC0-A195-291A08BB03AA Free histamine H7125_SIGMA HMS1362G19 HMS1792G19 HMS1990G19 HSDB 3338 HSM Histamine Histamine (DCF) Histamine Base Histamine [USAN] Histamine, Free Base Histaminum | Histaminum (TN) IDI1_000308 IDI1_002144 Imidazole-4-ethylamine Istamina Istamina [Italian] KBio1_000308 KBio2_000457 KBio2_001325 KBio2_003025 KBio2_003893 KBio2_005593 KBio2_006461 KBio3_000853 KBio3_000854 KBio3_001344 KBioGR_000457 KBioGR_001580 KBioSS_000457 KBioSS_001325 L-Histamin base L-Histamine L-histamine L000292 LS-75835 Lopac-H-7250 Lopac0_000595 MLS000069447 MolPort-001-785-597 MolPort-002-042-264 NCGC00015513-01 NCGC00015513-08 NCGC00093371-02 NCGC00093371-03 NCGC00093371-04 NCGC00093371-05 NINDS_000308 NSC 33792 NSC33792 SDCCGMLS-0066601.P001 SMP1_000151 SMR000059091 SPBio_000729 ST073926 STK346752 STOCK5S-55669 Spectrum2_000665 Spectrum3_000452 Spectrum4_000960 Spectrum5_000796 Spectrum_000845 Theramine UNII-820484N8I3 WLN: T5M CNJ D2Z ZERO/004089 [3H]histamine b-Imidazolyl-4-ethylamine beta-Aminoethylglyoxaline beta-Aminoethylimidazole beta-Aminothethylglyoxaline beta-Imidazolyl-4-ethylamine beta-aminothethylglyoxaline bmse000744 histamine nchembio.87-comp54 nchembio714-comp1 |
| | 48 | | Sirolimus | approved, investigational | Phase 1, Phase 2 | 1797 | 53123-88-9 | 5284616, 6436030, 46835353 | (-)-Rapamycin (-)-rapamycin 1fkb 1pbk 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone 53123-88-9 A422989, NSC226080 AC-722 AC1L1JH9 AC1L7MJ9 AC1L9ZMV AY 22989 AY-22989 AY22989 Ambotz53123-88-9 Antibiotic AY 22989 BIDD:PXR0165 Bio1_000293 Bio1_000782 Bio1_001271 Bio2_000375 Bio2_000855 BiomolKI2_000084 C07909 C51H79NO13 CBiol_002007 CCRIS 9024 CHEBI:100923 CHEBI:9168 CHEMBL413 CID10213190 CID10795871 CID11949238 CID11959112 CID313006 CID478951 CID5040 CID5284616 CID5358081 CID5374464 CID5460439 CID5497196 CID5924240 CID6436030 CID6610270 CID6610346 CID6711160 CID6713081 CID9833581 CID9854379 CID9854380 CID9962926 CID9962928 D00753 DB00877 DE-109 DivK1c_006936 | FT-0082351 HMS2089A21 HSDB 7284 KBio1_001880 KBio2_000410 KBio2_002978 KBio2_005546 KBio3_000779 KBio3_000780 KBioGR_000410 KBioSS_000410 LCP-Siro LMPK06000003 LS-143290 MLS000028373 MS-R001 MolMap_000043 MolPort-003-959-433 NCGC00021305-05 NCI60_001851 NCIMech_000355 NSC 226080 NSC226080 Perceiva QTL1_000069 R0395_SIAL R0395_SIGMA RAP RAPA RPM Rapammune Rapamune Rapamune (TN) Rapamycin Rapamycin (TN) Rapamycin C-7, analog 4 Rapamycin Immunosuppressant Drug Rapamycin from Streptomyces hygroscopicus S1039_Selleck SIIA 9268A SILA 9268A SILA9268A SMP1_000255 SMR000058564 Sirolimus Sirolimus (RAPAMUNE) Sirolimus (USAN/INN) Sirolimus [USAN:BAN:INN] Sirolimus, Rapamune,Rapamycin SpecPlus_000840 UNII-W36ZG6FT64 UNM-0000358684 WY-090217 Wy 090217 heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy nchembio.100-comp4 nchembio.2007.42-comp2 nchembio.79-comp1 nchembio762-comp1 nchembio883-comp3 rapamycin sirolimus |
| | 49 | | Temozolomide | approved, investigational | Phase 2, Phase 1 | 662 | 85622-93-1 | 5394 | 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide 3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide 3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one 85622-93-1 AC-758 AC1L1K9B BIDD:GT0204 BRN 5547136 Bio-0147 C047246 C6H6N6O2 CCRG 81045 CCRG-81045 CCRIS 8996 CHEBI:153686 CHEMBL810 CID5394 CPD000466338 D06067 DB00853 Essex brand of temozolomide HMS2051O12 HMS2090B08 I06-0149 I14-1943 LS-80558 M B 39831 M & B 39831 M&B 39831 M&B-39831 | M-39831 MB 39831 MLS000759447 MLS001424028 MLS002701861 Methazolastone NCGC00167429-01 NCGC00167429-02 NCI60_003316 NSC 362856 NSC-362856 NSC362856 SAM001246636 SMR000466338 STK623541 Sch 52365 Sch-52365 Schering brand of temozolomide Schering-Plough brand of temozolomide TL8005593 TMZ TMZ-Bioshuttle Temodal Temodal (TN) Temodar Temozolamide Temozolodida Temozolodida [Spanish] Temozolomid Temozolomida Temozolomide Temozolomide (JAN/USAN/INN) Temozolomide [INN:BAN] Temozolomidum Temozolomidum [Latin] Témozolomide UNII-YF1K15M17Y ZINC01482184 m & b 39831 temozolomide |
| | 50 | | Miconazole | approved, investigational | Phase 1, Phase 2 | 3026 | 22916-47-8 | 4189 | (+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole 1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole 1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole 1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole 1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole 1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole 1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole 22832-87-7 (NITRATE) 22916-47-8 75319-47-0 AB00053500 AC1L1HM1 AKOS001574474 Aflorix(nitrate) Albistat(nitrate) Andergin(nitrate) BPBio1_000279 BRD-A82396632-001-03-0 BRD-A82396632-008-02-7 BRN 0965511 BSPBio_000253 BSPBio_002033 CCRIS 7924 CHEBI:6923 CHEMBL91 CID4189 CPD-4501 Conofite(nitrate) D00416 DB01110 Dactarin Daktarin IV Daktarin iv Desenex DivK1c_000156 EINECS 245-324-5 Epi-Monistat(nitrate) Femizol-M Florid(nitrate) Gyno-Daktar(nitrate) HMS1568M15 HMS2090B21 I14-14342 IDI1_000156 Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI) KBio1_000156 KBio2_001445 KBio2_004013 KBio2_006581 KBio3_001533 KBioGR_000581 KBioSS_001445 LS-78378 Lotrimin AF(nitrate) MCZ MJR 1762 MLS002222203 Makesense Micantin (nitrate) Micatin | Miconasil Nitrate Miconazol Miconazol [INN-Spanish] Miconazole Miconazole (JP15/USP/INN) Miconazole 3 Miconazole 3 Combination Pack Miconazole 7 Combination Pack Miconazole [USAN:BAN:INN:JAN] Miconazole nitrate salt Miconazole-7 Miconazolo Miconazolo [DCIT] Miconazolum Miconazolum [INN-Latin] Micozole Minostate MolPort-002-557-553 Monazole 7 Monista (nitrate) Monistat Monistat (TN) Monistat 1 Combination Pack Monistat 3 Dual-Pak Monistat 3 Vaginal Ovules Monistat 5 Tampon Monistat 7 Dual-Pak Monistat 7 Vaginal Suppositories Monistat Dual- PAK Monistat IV Monistat iv (TN) Monistat iv (tn) Monistat-Derm NCI60_001353 NCI60_001380 NINDS_000156 NSC 170986 NSC169434 NSC170986 Novo-Miconazole Vaginal Ovules Oprea1_091955 Oravig Prestwick0_000067 Prestwick1_000067 Prestwick2_000067 Prestwick3_000067 Prestwick_335 R 18134 R-14,889 Rash Relief Antifungal SMR001307249 SPBio_000976 SPBio_002174 STK834405 STOCK1S-93556 Spectrum2_001048 Spectrum3_000507 Spectrum4_000061 Spectrum5_001297 Spectrum_000965 UNII-7NNO0D7S5M Vusion Zimycan imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI) miconazole |
|
Interventional clinical trials: (show top 50)
(show all 72)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | Radiation Therapy in Treating Patients Who Have Undergone Surgery for Soft Tissue Sarcoma of the Arms, Hands, Legs, or Feet | Completed | NCT00423618 | Phase 3 | | 2 | Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis | Completed | NCT00091351 | Phase 3 | | 3 | Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma | Completed | NCT00061984 | Phase 3 | | 4 | Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma | Completed | NCT00003212 | Phase 3 | | 5 | Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma | Completed | NCT00003052 | Phase 3 | | 6 | Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma | Completed | NCT00002764 | Phase 3 | | 7 | Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma | Completed | NCT00002641 | Phase 3 | | 8 | Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma | Completed | NCT00002898 | Phase 3 | | 9 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | Recruiting | NCT02180867 | Phase 2, Phase 3 | | 10 | Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy | Recruiting | NCT01710176 | Phase 3 | | 11 | Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma | Recruiting | NCT00334854 | Phase 3 | | 12 | Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma | Active, not recruiting | NCT00346164 | Phase 3 | | 13 | Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors | Terminated | NCT00427583 | Phase 2, Phase 3 | | 14 | Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma | Terminated | NCT01189253 | Phase 2, Phase 3 | | 15 | Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer | Terminated | NCT01132547 | Phase 3 | | 16 | S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor | Completed | NCT00068367 | Phase 2 | | 17 | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors | Completed | NCT00304083 | Phase 2 | | 18 | Sorafenib and Dacarbazine in Soft Tissue Sarcoma | Completed | NCT00837148 | Phase 2 | | 19 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | Completed | NCT01154452 | Phase 1, Phase 2 | | 20 | Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma | Completed | NCT00949325 | Phase 1, Phase 2 | | 21 | Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma | Completed | NCT00245102 | Phase 2 | | 22 | Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases | Completed | NCT00154388 | Phase 2 | | 23 | BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors | Completed | NCT00526149 | Phase 2 | | 24 | Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas | Completed | NCT00474994 | Phase 2 | | 25 | Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma | Completed | NCT00053794 | Phase 2 | | 26 | Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma | Completed | NCT00041249 | Phase 2 | | 27 | Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma | Completed | NCT00041236 | Phase 2 | | 28 | STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma | Completed | NCT00006357 | Phase 1, Phase 2 | | 29 | Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma | Completed | NCT00003939 | Phase 2 | | 30 | Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma | Completed | NCT00031915 | Phase 2 | | 31 | Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma | Completed | NCT00589784 | Phase 2 | | 32 | Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma | Recruiting | NCT02452554 | Phase 2 | | 33 | PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors | Recruiting | NCT02584647 | Phase 1, Phase 2 | | 34 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | Recruiting | NCT02601209 | Phase 1, Phase 2 | | 35 | Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma | Recruiting | NCT01532687 | Phase 2 | | 36 | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | Recruiting | NCT02584309 | Phase 2 | | 37 | A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma | Recruiting | NCT02601950 | Phase 2 | | 38 | Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma | Recruiting | NCT01883518 | Phase 1, Phase 2 | | 39 | SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors | Active, not recruiting | NCT01661283 | Phase 2 | | 40 | SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) | Active, not recruiting | NCT02008877 | Phase 1, Phase 2 | | 41 | Trial of Dasatinib in Advanced Sarcomas | Active, not recruiting | NCT00464620 | Phase 2 | | 42 | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma | Active, not recruiting | NCT00112463 | Phase 2 | | 43 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | Active, not recruiting | NCT01614795 | Phase 2 | | 44 | Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma | Active, not recruiting | NCT00410462 | Phase 2 | | 45 | Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma | Active, not recruiting | NCT00003718 | Phase 2 | | 46 | A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery | Not yet recruiting | NCT02691026 | Phase 2 | | 47 | Alisertib in Treating Patients With Advanced or Metastatic Sarcoma | Suspended | NCT01653028 | Phase 2 | | 48 | Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) | Terminated | NCT01418001 | Phase 1, Phase 2 | | 49 | Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma | Terminated | NCT00740597 | Phase 2 | | 50 | Proton Radiation Therapy for Spinal Tumors | Withdrawn | NCT01567787 | Phase 2 |
|
